| Targeting multidrug resistance in cancer G Szakács, JK Paterson, JA Ludwig, C Booth-Genthe, MM Gottesman Nature reviews Drug discovery 5 (3), 219-234, 2006 | 4464 | 2006 |
| Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system B Sarkadi, L Homolya, G Szakács, A Váradi Physiological reviews 86 (4), 1179-1236, 2006 | 1005 | 2006 |
| The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox) G Szakács, A Váradi, C Özvegy-Laczka, B Sarkadi Drug discovery today 13 (9-10), 379-393, 2008 | 797 | 2008 |
| Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells G Szakács, JP Annereau, S Lababidi, U Shankavaram, A Arciello, ... Cancer cell 6 (2), 129-137, 2004 | 706 | 2004 |
| Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells C Özvegy, T Litman, G Szakács, Z Nagy, S Bates, A Váradi, B Sarkadi Biochemical and biophysical research communications 285 (1), 111-117, 2001 | 454 | 2001 |
| Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain E Bakos, R Evers, G Szakács, GE Tusnády, E Welker, K Szabó, ... Journal of Biological Chemistry 273 (48), 32167-32175, 1998 | 437 | 1998 |
| MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping AJ Smith, A Van Helvoort, G Van Meer, K Szabó, E Welker, G Szakács, ... Journal of Biological Chemistry 275 (31), 23530-23539, 2000 | 371 | 2000 |
| The controversial role of ABC transporters in clinical oncology A Tamaki, C Ierano, G Szakacs, RW Robey, SE Bates Essays in biochemistry 50, 209-232, 2011 | 291 | 2011 |
| Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties C Hegedűs, C Özvegy‐Laczka, A Apati, M Magocsi, K Nemet, L Őrfi, ... British journal of pharmacology 158 (4), 1153-1164, 2009 | 281 | 2009 |
| Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer JA Ludwig, G Szakács, SE Martin, BF Chu, C Cardarelli, ZE Sauna, ... Cancer research 66 (9), 4808-4815, 2006 | 239 | 2006 |
| Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance G Szakacs, MD Hall, MM Gottesman, A Boumendjel, R Kachadourian, ... Chemical reviews 114 (11), 5753-5774, 2014 | 238 | 2014 |
| Synthesis, activity, and pharmacophore development for isatin-β-thiosemicarbazones with selective activity toward multidrug-resistant cells MD Hall, NK Salam, JL Hellawell, HM Fales, CB Kensler, JA Ludwig, ... Journal of medicinal chemistry 52 (10), 3191-3204, 2009 | 218 | 2009 |
| Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters M Okabe, G Szakács, MA Reimers, T Suzuki, MD Hall, T Abe, ... Molecular cancer therapeutics 7 (9), 3081-3091, 2008 | 205 | 2008 |
| Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1) É Bakos, R Evers, G Calenda, G E. Tusnády, G Szakács, A Váradi, ... Journal of cell science 113 (24), 4451-4461, 2000 | 162 | 2000 |
| Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane JK Paterson, S Shukla, CM Black, T Tachiwada, S Garfield, S Wincovitch, ... Biochemistry 46 (33), 9443-9452, 2007 | 160 | 2007 |
| Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? A Brózik, C Hegedüs, Z Erdei, T Hegedűs, C Özvegy-Laczka, G Szakács, ... Expert opinion on drug metabolism & toxicology 7 (5), 623-642, 2011 | 140 | 2011 |
| Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells JK Lee, KJ Bussey, FG Gwadry, W Reinhold, G Riddick, SL Pelletier, ... Genome Biology 4 (12), R82, 2003 | 136 | 2003 |
| Identification of compounds selectively killing multidrug-resistant cancer cells D Türk, MD Hall, BF Chu, JA Ludwig, HM Fales, MM Gottesman, ... Cancer research 69 (21), 8293-8301, 2009 | 134 | 2009 |
| Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance VFS Pape, S Tóth, A Füredi, K Szebényi, A Lovrics, P Szabó, M Wiese, ... European Journal of Medicinal Chemistry 117, 335-354, 2016 | 129 | 2016 |
| Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents Á Póti, H Gyergyák, E Németh, O Rusz, S Tóth, C Kovácsházi, D Chen, ... Genome biology 20 (1), 240, 2019 | 125 | 2019 |
